← Back

Chison Medical Technologies Co Ltd

Chison Medical Technologies Co., Ltd. develops, manufactures, and sells diagnostic ultrasound systems in China and internationally. Its products include cart-based, portable, handheld, and B&W ultrasound systems for radiology, cardiovascular, women's health, general imaging, POC, and primary care applications. The company also offers SonoAI. Founded in 1996, it is based in Wuxi, China.

Country
Price · split & dividend adjusted
News & notes moving 688358.CG
688358.CG2

Chison Medical Technologies Half-Year Report: Revenue of 241 Million Yuan, Proposed Cash Dividend of 39.24 Million Yuan

Chison Medical Technologies released its 2026 semi-annual report on the evening of August 27. In the first half of the year, the company achieved operating revenue of 241 million yuan, up 2.24 percent year on year, while net profit attributable to shareholders of the listed company was 68.96 million yuan, roughly flat compared with the same period last year. The company plans to distribute a cash dividend of 3.50 yuan per ten shares, before tax, to all shareholders, totaling 39.24 million yuan before tax, accounting for 56.91 percent of first-half net profit. On the product side, the company continued to refine its SonoFamily product matrix, officially launched the SonoGo series, strengthened AI computing power in the SonoPort series, and expanded horizontally into the veterinary ultrasound field. In research and development, the company's first-half R&D expenses accounted for 16.52 percent of operating revenue, and it held a total of 697 intellectual property rights, including 167 invention patents. In terms of globalization, the company has established sales networks in more than 100 countries and regions worldwide and deepened cooperation with international companies such as Canon, BD, and Philips.
证券时报·22dRead more →
688358.CG

Chison Medical's first-half net profit attributable to parent was 68.96 million yuan, down 1.1% year on year

Chison Medical released its 2026 interim report. Net profit attributable to the parent in the first half was 68.96 million yuan, down 1.1% year on year, while operating revenue was 241 million yuan, up 2.2% year on year. In the second quarter, operating revenue was 114 million yuan, up 5.3% year on year, and net profit attributable to the parent was 22.93 million yuan, down 18.3% year on year. As of the end of the second quarter, total assets were 1.602 billion yuan, up 0.5% from the end of the previous year, and net assets attributable to the parent were 1.368 billion yuan, down 1.1% from the end of the previous year. The company said overall operations remained stable. Despite external pressures such as trade frictions and supply chain restructuring, it showed strong operational resilience thanks to three decades of industry experience and a globalized footprint. In addition, the SonoMax series has obtained EU CE certification, China medical device registration, and US FDA market access approval.
财中社·23dRead more →
688358.CG

Chison Medical Technologies Responds to SSE Inquiry: Q4 2025 Net Profit Plunges 46.36% Mainly Due to Shrinking Exchange Gains

Chison Medical Technologies, in response to the Shanghai Stock Exchange's annual report inquiry letter, stated that its net profit in the fourth quarter of 2025 fell sharply by 46.36% year-on-year, with the core reason being a significant year-on-year shrinkage in exchange gains caused by major fluctuations in the US dollar exchange rate during the period. The company incurred an exchange loss of 5.95 million yuan for the full year. After excluding the impact of exchange gains and losses, the decline in net profit was broadly in line with the decline in revenue. Full-year revenue for 2025 decreased by 7.02% year-on-year, mainly because US tariff hikes led local customers to scale back purchases of portable color ultrasound devices, coupled with domestic centralized procurement extending procurement cycles. Fourth-quarter revenue fell 12.97% year-on-year, primarily due to the delivery of some orders being postponed to the first quarter of 2026 for recognition. The company stated that first-quarter 2026 revenue reached 127 million yuan, roughly flat year-on-year, while net profit grew by 10.60%, indicating that operations are showing signs of bottoming out and stabilizing. It is also advancing AI product upgrades and a global localization layout to improve performance.
南方财经网·72dRead more →